• In April 2026, Thermo Fisher Scientific announced multiple collaborations, including a data partnership with HealthVerity and a proteomics-focused alliance with Precision Health Research Singapore, alongside new cell therapy manufacturing and biologics cell line development platforms and a global distribution deal for therapeutic drug monitoring assays.
• Together, these moves deepen Thermo Fisher’s role across clinical development, precision health and advanced biologics manufacturing by tying its instruments, software and services more tightly into large data-rich research programs and everyday clinical workflows.
• We’ll now examine how expanded access to HealthVerity’s large-scale healthcare datasets could influence Thermo Fisher’s existing investment narrative around AI-enabled clinical development.

Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Thermo Fisher Scientific Investment Narrative Recap

To own Thermo Fisher, I think you need to believe it can keep deepening its role as an end to end partner in drug development, diagnostics and advanced biomanufacturing. Near term, the key catalyst remains execution on high impact innovation and data enabled services, while the biggest risk is sustained pressure in capital sensitive segments like Analytical Instruments and China. The April collaborations and launches support the long term story, but do not materially change those near term drivers.

The HealthVerity data collaboration is most relevant here, because it directly reinforces Thermo Fisher’s AI enabled clinical development narrative. By giving the PPD clinical research business access to more than 270 million de identified U.S. patient records and linked datasets, it strengthens offerings in trial feasibility, recruitment and real world evidence. That sits squarely against the current catalyst of deeper integration with biopharma workflows through differentiated data, software and services.

Yet, even with these positives, investors should also be aware of how persistent margin pressure in Analytical Instruments could...

Thermo Fisher Scientific's narrative projects $50.0 billion revenue and $9.0 billion earnings by 2028. This requires 5.0% yearly revenue growth and a $2.4 billion earnings increase from $6.6 billion today.

Uncover how Thermo Fisher Scientific's forecasts yield a $663.96 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming Thermo Fisher could lift revenue to about US$55.9 billion and earnings to roughly US$9.9 billion by 2029, which is far more bullish than consensus. When you compare that to concerns about protectionism and tariff pressure on margins, it shows just how differently you and other investors might view the same company and why it can be useful to explore several competing narratives around Thermo Fisher’s AI driven collaborations and product launches.

Explore 12 other fair value estimates on Thermo Fisher Scientific - why the stock might be worth 42% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Thermo Fisher Scientific research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Thermo Fisher Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Thermo Fisher Scientific's overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.